Tonix Pharmaceuticals Expands Preclinical Pipeli"±γne with Triple Reuptake In< ≥λhibitor, TNX-1600, for th₽εe Treatment of PTSD
Tonix Pharmaceuticals Holding Corp., a cliδ✘σ$nical-stage biopharmaceutical company, announc₽λed today an exclusive agreement t✔≈πo in-license a triple reuptake ©γinhibitor (TRI), TNX-16® 00 (formerly D-578), to treat posttrauma ♦≥tic stress disorder (PTSD) and potentiall♣¥y other central nervous system₩ (CNS) disorders. The co♥↓mpound was developed and pharmaco&♣λ™logically characterized β₩♥¶by Aloke Dutta, Ph.D., professor of Phar©→∑maceutical Sciences at→$£ Wayne State University, with fundingφ© from a National Institut©≈ es of Health grant (g©↔rant number MH084888), and the✘ patents covering the compounds πwere licensed to TRImaran Phaλ↔rma, Inc. (TRImaran). The transaction anεβnounced today is a lic£€' ense agreement with Wayne State and an asset aα♣cquisition with TRImaran.“We are exci ¶☆ted to expand our pip♦β≈eline and are looking forward♠≥ to developing TNX-1π>600 as a potential treatment for¥€λ PTSD,” said Seth Ledermεδan, M.D., Tonix's President and Chief § Executive Officer. “We p≈↕∏lan to utilize our cliniδ'αcal experience in PTSD to evaluate₩★ the therapeutic benefit of TNX-1600. PTSD is ≤★'a heterogeneous condit≠ ion, so we believe different♦↔ PTSD patients may respond to different medi∞•cines. In some cases, more than one drug will be >€♦required for effective ¥εtreatment. TNX-1600 is our third drug candida₹ te in development for PTSD. Our×'¶ most advanced candida♥₽§te is TNX-102 SL, which ≠ $♠is in Phase 3 develo☆₹pment. We are also developing TNX-601 which≥λ↕ε is entering a Phase 1 trial imminently. TNX-16£ >δ00 is in the pre-IND phase o₹$f development with encouragi©"ng data from animal models of PTSD.☆φ♥↓”Frank Bymaster, Chief Scientific Officer an÷☆d co-founder of TRIma$♦ran Pharma Inc. said, “T∞≠≠NX-1600 is a novel TRI that i ☆•®nhibits simultaneously the reupt¶✔♦ake of three key neurotransmitters: ser™ΩΩ<otonin, norepinephrinπ>♥σe and dopamine. Each of the•✘±se three neurotransmitters p✘εlays a key modulatory role in many CNS proceπ'sses. Inhibiting reuptake of all three may prγ∑ ↓ovide an effective treatme¶<nt for PTSD.”According to Dr. Alo§×ke Dutta, “We have developed an innovative tr±€¶♦iple reuptake inhibitor, D-578, ba ♥sed on a unique pyran mol♦ σecular scaffold to address th∏•♣e current therapeutic needs€←λ§ for PTSD and other ♥§<±neurological disorders. Based on our preliminar ÷y data, we expect a pharmacological synergy fro£γm their potent modulatory effect on<↓ the level of monoamine neu★α↔rotransmitters in the brain which sh¶★±∏ould facilitate effe €♦ctive treatment of these disor<♥ders.”Under the terms of the agreeme↕'nt, Tonix has been granted an exclusive licens$σ∞×e from Wayne State University for tech↔£≥↕nology and patents rela←ted to TNX-1600 and ot&αher pyran-based compounds. Another me¥"<mber of the class, D-473, has also shown e←♦ffects in a rodent model of depression.t♠εσσhe 2019 Asia-pacific Pharmaceutical IP Leade§→r Summit will be held in Beijing δ€ ↕on November 14-15, and will attract mor β₽★e than 500 industry experts ♥≠from domestic and foreign pharmaλπceutical companies, biotechnφ♦ology companies, governments, associatio★€ns, law firms, intellectual proper☆↓∞ty agents and other companies to attend. ®§£₹2019 Asia-pacific Pharmaceutical IP Leader Su✔∏ε₩mmit Official registration and co¥₽♣nsultation channels:Contact:An¶ε☆€nPhone: 021-65650305Email:Marketingγ←@zenseegroup.comhttp://en.zenseegroup.com/p/51>♥0934/